CD38 and plasma cell myeloma: Viola et al. demonstrated that daratumumab therapy decreased the count of total NK cells, but it activated CD38-negative NK cells and enhanced expression of CD80/CD86 T-cell costimulatory molecules on monocytes in patients with multiple myeloma.